Cargando…

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer

PURPOSE: We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival. PATIENTS AND METHODS: In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany (n = 111) were studied. Plasma YKL-4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schultz, Nicolai A., Christensen, Ib J., Werner, Jens, Giese, Nathalia, Jensen, Benny V., Larsen, Ole, Bjerregaard, Jon K., Pfeiffer, Per, Calatayud, Dan, Nielsen, Svend E., Yilmaz, Mette K., Holländer, Niels H., Wøjdemann, Morten, Bojesen, Stig E., Nielsen, Kaspar R., Johansen, Julia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694124/ https://www.ncbi.nlm.nih.gov/pubmed/23840582 http://dx.doi.org/10.1371/journal.pone.0067059

Ejemplares similares

Combined plasma C‐reactive protein, interleukin 6 and YKL‐40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer
por: Videmark, Alex N., et al.
Publicado: (2022)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects
por: Nielsen, Kaspar R, et al.
Publicado: (2011)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis
por: Dolin, Troels Gammeltoft, et al.
Publicado: (2021)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

A polymorphism associated with increased levels of YKL-40 and the risk of early onset of lone atrial fibrillation
por: Henningsen, Kristoffer M A, et al.
Publicado: (2013)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2019)

Decay of /sup 199m, g/Po: isomeric transitions in /sup 199/PO and /sup 199/BI
por: Bingham, C R, et al.
Publicado: (1981)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept Alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
por: Knudsen, Lene Surland, et al.
Publicado: (2009)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

NetCTLpan: pan-specific MHC class I pathway epitope predictions
por: Stranzl, Thomas, et al.
Publicado: (2010)

Metagenomic Analysis of Therapeutic PYO Phage Cocktails from 1997 to 2014
por: Villarroel, Julia, et al.
Publicado: (2017)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study
por: Nielsen, Sune F, et al.
Publicado: (2012)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

Immune response to Mycoplasma pneumoniae P1 and P116 in patients with atypical pneumonia analyzed by ELISA
por: Drasbek, Mette, et al.
Publicado: (2004)

YKL-40 levels are independently associated with albuminuria in type 2 diabetes
por: Røndbjerg, Anne K, et al.
Publicado: (2011)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017)

YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors: An immunohistochemical study of 49 tumors
por: Harving, Mette L, et al.
Publicado: (2014)

Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5m3kiu2hnfqg3h8q6ea71qp50f